基于肠促胰素的治疗与2型糖尿病患者死亡率:系统综述与荟萃分析
该系统综述与荟萃分析纳入189项随机对照试验(n=155145),比较GLP-1受体激动剂或DPP-4抑制剂与安慰剂或活性降糖药对2型糖尿病患者全因死亡率的影响,结果显示基于肠促胰素的治疗与对照组全因死亡率无差异(OR 0.96,95%CI 0.90-1.02,I²=0%,中等质量证据),当前证据不支持其增加全因死亡率。
要点
- 纳入189项随机对照试验共155145例2型糖尿病患者,偏倚风险为低至中等。
- 基于肠促胰素的治疗与对照组全因死亡率无差异(OR 0.96,95%CI 0.90-1.02,I²=0%)。
- 亚组分析提示GLP-1受体激动剂可能有死亡率获益而DPP-4抑制剂无,但该亚组假设可信度低。
核心结论
- 当前证据不支持基于肠促胰素的治疗会增加2型糖尿病患者全因死亡率的说法。
- 需进一步研究以检验GLP-1受体激动剂与DPP-4抑制剂之间效应是否存在差异。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane对照试验中心注册库(CENTRAL)和ClinicalTrials.gov。
- 纳入比较GLP-1受体激动剂或DPP-4抑制剂与安慰剂或活性降糖药的随机对照试验,共189项试验(n=155145),均为低至中等偏倚风险。
- 由成对评价者独立筛选文献、评估偏倚风险并提取数据,主要采用Peto法合并效应估计,并采用其他统计方法进行敏感性分析,对六个预设假设进行荟萃回归以探索异质性,采用GRADE方法评价证据质量。
主要发现
- 189项试验中77项未报告死亡事件,112项在151614例患者中报告3888例死亡。
- 189项试验的荟萃分析显示基于肠促胰素的药物与对照组全因死亡率无差异(1925/84136 vs 1963/67478;OR 0.96,95%CI 0.90-1.02,I²=0%;5年内每1000例患者风险差为减少3例事件(95%CI 减少7例至增加1例);中等质量证据)。
- 结果提示GLP-1受体激动剂可能有死亡率获益而DPP-4抑制剂无,但该亚组假设可信度低。
- 敏感性分析显示效应估计无重要差异。
关键数值与推荐
- 全因死亡率:基于肠促胰素的药物组1925/84136 vs 对照组1963/67478,OR 0.96(95%CI 0.90-1.02),I²=0%,风险差为5年内每1000例患者减少3例事件(95%CI 减少7例至增加1例),中等质量证据。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 亚组假设(GLP-1受体激动剂与DPP-4抑制剂死亡率效应不同)可信度低。
- 需进一步研究以检验GLP-1受体激动剂与DPP-4抑制剂之间效应是否存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To assess the impact of incretin based treatment on all cause mortality in patients with type 2 diabetes.Design Systematic review and meta-analysis of randomised trials.Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov.Eligibility criteria Randomised controlled trials that compared glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors with placebo or active anti-diabetic drugs in patients with type 2 diabetes.Data collection and analysis Paired reviewers independently screened citations, assessed risk of bias of included studies, and extracted data. Peto's method was used as the primary approach to pool effect estimates from trials, sensitivity analyses were carried out with other statistical approaches, and meta-regression was applied for six prespecified hypotheses to explore heterogeneity. The GRADE approach was used to rate the quality of evidence.Results 189 randomised controlled trials (n=155 145) were included, all of which were at low to moderate risk of bias; 77 reported no events of death and 112 reported 3888 deaths among 151 614 patients. Meta-analysis of 189 trials showed no difference in all cause mortality between incretin drugs versus control (1925/84 136 v 1963/67 478; odds ratio 0.96, 95% confidence interval 0.90 to 1.02, I2=0%; risk difference 3 fewer events (95% confidence interval 7 fewer to 1 more) per 1000 patients over five years; moderate quality evidence). Results suggested the possibility of a mortality benefit with GLP-1 agonists but not DPP-4 inhibitors, but the subgroup hypothesis had low credibility. Sensitivity analyses showed no important differences in the estimates of effects.Conclusions Current evidence does not support the suggestion that incretin based treatment increases all cause mortality in patients with type 2 diabetes. Further studies are warranted to examine if the effect differs between GLP-1 agonists versus DPP-4 inhibitors.
引用
- Liu J, Li L, Deng K, et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017. PMID: 28596247. doi:10.1136/bmj.j2499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。